Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Severe Hypertriglyceridemia
Interventions: ARO-APOC3, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 33
States / cities: Beverly Hills, California • Palm Springs, California • Boca Raton, Florida + 26 more

Conditions: HIV Infections, Lipodystrophy
Interventions: Pravastatin sodium, Fenofibrate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 57
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 33 more

Conditions: Obesity, Obesity, Abdominal, Metabolic Syndrome, Weight Loss
Interventions: Vestibular nerve stimulator, Sham vestibular stimulation; Device
Lead sponsor: Neurovalens Ltd.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Lipodystrophy
Interventions: Metreleptin; Biological
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 14 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Severe Hypertriglyceridemia
Interventions: Plozasiran, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 17
States / cities: Los Angeles, California • Santa Clarita, California • New Haven, Connecticut + 14 more

Conditions: Hyperlipidemias
Interventions: DASH eating plan with eggs, DASH eating plan without eggs; Other
Lead sponsor: Griffin Hospital; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Atherosclerosis, Hyperlipidemia, Hypertension, Diabetes Mellitus
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Elevated Triglycerides, Diabetes, Cardiovascular Disease, Dyslipidemia
Interventions: Fructose + Glucose Beverage; Other
Lead sponsor: The Rogosin Institute; Other
Eligibility: 18 Years to 35 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: New York, New York

Conditions: Hyperlipidemias, Cardiovascular Diseases
Interventions: Dried blood spot testing and phlebotomy; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Adverse Effects
Interventions: Frozen capsule, Capsule with food, Capsule without food, Capsule with milk; Dietary Supplement
Lead sponsor: University of Mississippi, Oxford; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Peripheral Artery Disease, Amputation, Smoking, Diabetes, Hypercholesterolemia, Hypertension
Interventions: ABI using QuantaFlo™; Device
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 238 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hyperlipidemias
Interventions: Fruit and vegetable deliveries; Dietary Supplement
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hypertriglyceridemia, Cardiovascular Disease
Interventions: Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 89
States / cities: Muscle Shoals, Alabama • Chandler, Arizona • Phoenix, Arizona + 78 more

Conditions: Hyperlipoproteinemia Type I, Hypertriglyceridemia
Interventions: Orlistat; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 8 Years to 18 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pre-Diabetic, Overweight, Obesity
Interventions: Exercise & Dietary Supplement; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypertriglyceridemia
Interventions: ARI-3037MO, Placebo; Drug
Lead sponsor: Arisaph Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Tustin, California • Louisville, Kentucky • Auburn, Maine + 2 more

Conditions: Hypercholesterolaemia
Interventions: Enlicitide Decanoate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Hallandale, Florida • Miami, Florida • Orlando, Florida + 1 more

Conditions: Obesity, Insulin Resistance, Obesity in Diabetes, Nutritional and Metabolic Diseases, Hyperlipidemia, Hyperglycemia, Cardiovascular Diseases
Interventions: Placebo-Control, Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d); Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Gestational Diabetes, Hyperlipidemia
Interventions: Total Cholesterol, Triglyceride, HDL, LDL; Other
Lead sponsor: Baystate Medical Center; Other
Eligibility: 16 Years to 40 Years · Female only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Familial Hypercholesterolaemia
Interventions: Alert-based computerized decision support; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyperlipidemia, Dyslipidemia
Interventions: NK-104-CR, Livalo® IR, Placebo (for NK-104-CR), Placebo (for Livalo® IR); Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 69
States / cities: Foley, Alabama • Huntsville, Alabama • Montgomery, Alabama + 66 more

Conditions: Hypercholesterolemia
Interventions: CAT-2054, Placebo, CAT-2054-C, Atorvastatin; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions: Obicetrapib; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 19
States / cities: Anniston, Alabama • Huntington Park, California • Los Angeles, California + 15 more

Conditions: HIV Infection, Hyperlipidemia
Interventions: Atazanavir, current antiretroviral regimen; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 2 more

Search by objective public record fields.

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

Vestibular Stimulation to Trigger Adipose Loss Clinical Trial

Short-term Effects of Leptin in People With Lipodystrophy

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

Daily Inclusion of Eggs in a Heart-Healthful Dietary Pattern in Hyperlipidemic Adults

Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease

Change of Fructose to Fat in South Asians

Dried Blood Spot- Statin Pilot Study

Method of Fish Oil Administration on Patient Compliance

Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease

Food Pharmacy at Oregon Health & Science University (OHSU) Knight Cardiovascular Institute (KCVI)

[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL

Orlistat for the Treatment of Type I Hyperlipoproteinemia

Feasibility of an Interval Exercise and Nutrition Intervention to Reduce Cardiovascular Disease Risk Factors

Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)

Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)

Lipid Metabolism in Gestational Diabetes

Computerized Decision Support for Identification and Management of Familial Hypercholesterolemia

Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia

A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study